Calstang, The resumption of eIND and expected o
Post# of 148147
(Total Views: 629)
Posted On: 12/29/2020 4:28:38 PM
Calstang,
The resumption of eIND and expected open label extension argue that the FDA believes leronlimab works.In and of themselves, eIND and open label administration provide little more than aggregated anecdotal evidence. It is as simple as that.
Witness the results for invermectin, HCQ, Tocilizumab, mesonlast’s Remestemcel and so forth.
Cytodyn is on the cusp of profound success because the randomly assorted, double blinded CD12 with mortality endpoint appears to be a success.
The great work of Drs Seethamraju, Yang, Patterson et al with the eIND got us here. Theirs were the important first steps.
However, it is only CD12 results that will bring approval and put an end to the Covid deaths.
The resumption of eIND and expected open label extension argue that the FDA believes leronlimab works.In and of themselves, eIND and open label administration provide little more than aggregated anecdotal evidence. It is as simple as that.
Witness the results for invermectin, HCQ, Tocilizumab, mesonlast’s Remestemcel and so forth.
Cytodyn is on the cusp of profound success because the randomly assorted, double blinded CD12 with mortality endpoint appears to be a success.
The great work of Drs Seethamraju, Yang, Patterson et al with the eIND got us here. Theirs were the important first steps.
However, it is only CD12 results that will bring approval and put an end to the Covid deaths.
(8)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼